Chronic Hepatitis C Virus Infection
Conditions
Keywords
P1101, HCV, PEG-Intron
Brief summary
Primary objective: To demonstrate non-inferiority in sustained virologic response (SVR, undetectable HCV RNA at Follow up week 12) between PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily and P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily for the treatment of chronic HCV genotype 2 infection
Detailed description
Secondary objective: To determine and compare the efficacy, safety, tolerability and immunogenicity of PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily and P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily
Interventions
P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily
DRUGPEG-Intron + Ribavirin
PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily
Sponsors
PharmaEssentia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Adults ≥18 years of age (or other age required by local regulations); subjects who are over 70 years of age must be in generally good health. 2. Confirmed diagnosis of chronic hepatitis with HCV genotype 2 infection. Chronicity is defined as having proven clinical evidence of chronic hepatitis, e.g. a duration of disease longer than 24 weeks before dosing, OR positive for anti-HCV antibody and HCV RNA at screening with biopsy-proven chronic hepatitis C, OR fibrosis. 3. Compensated liver disease defined by normal or elevated ALT ≤10 x ULN, total bilirubin level \<2 mg/dL (except in Gilbert's syndrome), normal albumin, normal INR (INR ≤1.5) 4. Interferon treatment naïve: never received any interferon. 5. No other known form of chronic liver disease apart from chronic hepatitis C infection. But mild and moderate fatty liver diseases can be included. 6. Hemoglobin ≥12 g/dL in men or ≥11 g/dL in women, WBC count ≥3,000/mm3, ANC ≥1,500/mm3, platelet count ≥90,000/mm3; and estimated glomerular filtration rate \>60 mL/min. 7. Female and male subjects, and their partners of reproductive potential using effective means of contraception during the whole trial period. 8. Be able to attend all scheduled visits and to comply with all study procedures; 9. Be able to provide written informed consent.
Exclusion criteria
Any of the following is cause for exclusion from the study: 1. Decompensated liver disease, including overt clinical symptom and sign of complications related to portal hypertension. 2. Clinically significant illness or surgery within 4 weeks prior to dosing. 3. Any reason which, in the opinion of the investigator, would prevent the subject from participating in the study. 4. Positive test for hepatitis B surface antigen or human immunodeficiency virus at screening. 5. Clinically significant abnormal vital signs at screening. 6. Evidence of severe retinopathy by fundoscopy except age-related macular degeneration at screening. 7. Significant alcohol or illicit drug abuse within one year prior to the screening visit or refusal to abstain from excessive alcohol consumption as defined above or illicit drugs throughout the study. 8. Pregnant or breast feeding female subjects. 9. Therapy with any systemic anti-viral, anti-neoplastic, and immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) within 4 weeks prior to the first dose of study drug. 10. Use of an investigational drug or participation in an investigational drug trial within 4 weeks from the first dose. 11. Known clinically significant presence of any gastrointestinal pathology, clinically significant unresolved gastrointestinal symptoms, clinically significant liver (other than CHC) or clinically significant kidney disease (including but not limited to those with chronic renal failure on dialysis), or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug. 12. Hospital Anxiety and Depression Scale (HADS) score \>10 on depression scale at screening that indicates clinically significant presence of depression determined by investigators. 13. Clinically significant presence of severe neurological disorders, e.g. uncontrolled seizure disorders. 14. Clinically significant presence of severe cardiovascular conditions and severe pulmonary conditions (including but not limited to pulmonary infiltrates, pneumonia, pneumonitis, chronic obstructive lung disease), uncontrolled immunologic, uncontrolled autoimmune, uncontrolled endocrine, uncontrolled metabolic, haematological, severe coagulation disorders or severe blood dyscrasias or other severe uncontrolled systemic disease. 15. A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis; 16. Body organ transplant and are taking immunosuppressants; 17. History of malignant disease, including solid tumors and hematologic malignancies (except basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured, and carcinoma in situ of cervix); However, subjects who are cancer survivors not on maintenance therapy and who had no malignant diseases history within the past 5 years could be recruited. 18. History of or ongoing opportunistic infection. 19. Serious local infection or systemic infection within the 3 months prior to screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Subjects with undetectable serum HCV RNA at follow up week 12 | Follow Week 12 | Percentage of subjects with SVR12 (undetectable serum HCV RNA, i.e. \<12 IU/mL, at follow up week 12) in each treatment group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subjects with undetectable serum HCV RNA | Treatment Week 4, 8, 12, 24 and Follow Week 24 | Percentage of subjects with undetectable serum HCV RNA at treatment week 4, 8, 12, 24 (end of treatment) and follow up week 24 in each treatment group |
| Number of subjects with adverse events | Through study Follow Week 24 | Number of subjects with adverse events in each treatment group |
| Number of subjects with clinically significant laboratory abnormalities | Through study Follow Week 24 | Number of subjects with clinically significant laboratory abnormalities in each treatment group |
| Subjects with anti-drug antibodies | Follow Week 12 and 24 | Percentage of subjects with positive anti-drug antibodies (the anti-peginterferon and the anti-Peg) at follow up week 12 and 24 |
| Subjects with neutralizing antibody | Follow Week 12 and 24 | Percentage of subjects with positive neutralizing antibody at follow up week 12 and 24 |
Countries
China, South Korea, Taiwan
Outcome results
None listed